ANAVEX®2-73 Demonstrates Promising Clinical Benefits in Parkinson’s Disease Dementia Study
Anavex Life Sciences has announced encouraging results from a 48-week Phase 2 extension study of their lead drug candidate, ANAVEX®2-73 (blarcamesine), in patients with Parkinson’s disease dementia. The clinical-stage biopharmaceutical company focuses on developing innovative therapeutics for various neurodegenerative and neurodevelopmental disorders. In the study, ANAVEX®2-73 showed significant improvements across all efficacy endpoints. Patients experienced […]